<?xml version="1.0" encoding="UTF-8"?>
<p id="para0026">Due to time limitations, there have been few animal experiments related to COVID-19. Compound Qinlan Oral Liquid has a certain pharmacological effect in the rat model when combining COVID-19 disease with epidemic toxin closed lung syndrome, through inhibiting virus replication, improving gastrointestinal function, improving immunity, and decreasing inflammatory factor expression. A therapeutic effect was found in Compound Qinlan Oral Liquid in treating a combination of COVID-19 pneumonia with pestilence attacking lung syndrome (
 <xref rid="bib0005" ref-type="bibr">Bao et al., 2020</xref>). Reyanning Mixture could treat COVID-19 in mice with epidemic toxin closed lung syndrome. It has significant effects such as improving the gastrointestinal function and enhancing the autoimmune function of mice, and decreasing the expression of inflammatory factors in vivo, which would offer reference for clinical research (
 <xref rid="bib0005" ref-type="bibr">Bao et al., 2020</xref>).
</p>
